Axsome Therapeutics

Axsome Therapeutics is a publicly traded, fully integrated biopharmaceutical company focused on central nervous system conditions, including depression, Alzheimer’s disease agitation, migraine, narcolepsy, fibromyalgia, ADHD, excessive daytime sleepiness, binge eating disorder, shift work disorder, schizophrenia, epilepsy and smoking cessation. The company develops differentiated oral small-molecule therapies and commercializes its products in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm?utm_source=openai)) Axsome currently markets AUVELITY, SUNOSI and SYMBRAVO. AUVELITY is approved for major depressive disorder and agitation associated with dementia due to Alzheimer’s disease; SUNOSI is approved for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea; and SYMBRAVO is approved for acute treatment of migraine with or without aura. Its development portfolio includes AXS-05 for smoking cessation, solriamfetol for several additional CNS indications, AXS-12 for narcolepsy, AXS-14 for fibromyalgia, AXS-17 for epilepsy and AXS-20 for schizophrenia and potentially Tourette syndrome. ([axsometherapeuticsinc.gcs-web.com](https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-reports-second-quarter-2026-financial))